Chennai, India – January 7, 2019 – MobileODT, developer of the Enhanced Visual Assessment (EVA) System, will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared smart mobile colposcope. The project will perform the first large-scale pilot of Augmented Intelligence (AI) for use in the screening of cervical cancer.
This deployment will give healthcare professionals cutting edge, yet low-cost mobile technology to reach millions of women across India who previously had limited access to life-saving cervical exams.
Over 432 million women in India are at risk of developing cervical cancer, yet only 3.1% receive screening. Lack of equipment, qualified colposcopists, and socioeconomic conditions contribute to low screening numbers. When women do get screened with HPV testing or a Pap Smear, up to 80% with positive results do not return for treatment. Such loss of follow up can have deadly results for a highly treatable form of cancer when caught early.